- Details
- Pedro Barata and María Bourlon discuss the CheckMate 9ER trial's 55-month follow-up, revealing the enduring benefits of cabozantinib plus nivolumab over sunitinib in untreated advanced renal cell carcinoma. The trial highlights significant advancements in overall survival, progression-free survival, and response rates, alongside improved quality of life for patients. Dr. Bourlon emphasizes the tri...
|
- Details
- Pedro Barata and David Braun delve into the evolving landscape of biomarkers in renal cell carcinoma (RCC). Dr. Braun emphasizes the transition from histological analysis to advanced techniques like genomics and transcriptomics, highlighting their potential to differentiate between molecular subtypes of RCC and predict therapy responses. Specifically, transcriptomics could pave the way for tailore...
|
- Details
- Arun Azad discusses the LIBERTAS trial focusing on metastatic hormone-sensitive prostate cancer treatment with ADT plus apalutamide. The trial, aimed at improving patient outcomes and quality of life, explores the efficacy of deescalating therapy for patients achieving a PSA of less than 0.2 nanograms per milliliter after six months. The study includes a diverse patient population, irrespective of...
|
- Details
- Guillaume Grisay introduces the De-Escalate trial, a study focused on intermittent treatment for metastatic hormone-naive prostate cancer patients who have achieved a deep PSA response after induction therapy. This innovative approach aims to preserve overall survival while improving patients' quality of life by pausing ADT and AR pathway inhibitors, addressing the challenges of chronic toxicities...
|
- Details
- Neal Shore discusses the ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment strateg...
|
- Details
- Zach Klaassen and Joshua Meeks discuss the ongoing BCG shortage impacting bladder cancer treatment, tracing its origins back to production issues in 2012 and guideline changes in 2016 that increased BCG demand. They highlight the shift towards using Gemcitabine-Docetaxel (Gem/Doce) as both a salvage and primary treatment for high-risk bladder cancer due to its effectiveness and availability. The d...
|
- Details
- Shilpa Gupta discusses the challenges and progress of the MAIN-CAV study examining the combination of treatments for urothelial cancer in the U.S., impacted by a platinum drug shortage. Despite setbacks, efforts are underway to increase patient enrollment, with assistance from Canadian colleagues. The conversation with Dr. Sam Chang reveals no safety concerns with the combination of TKI and immuno...
|
- Details
- Judd Moul discusses a study focusing on the mortality risk associated with androgen deprivation therapy (ADT) in Black versus white patients with prostate cancer. The study, a comprehensive analysis of a large cohort, indicates that African-American ethnicity may be protective for survival in both castrate-resistant and castrate-sensitive prostate cancer. This contradicts earlier perceptions, espe...
|
- Details
- Leslie Ballas and Christophe Hennequin explore the findings of the GETUG-AFU 18 randomized trial, which evaluated the impact of radiotherapy dose escalation in high-risk prostate cancer patients receiving long-term androgen deprivation therapy (ADT). Conducted between 2009 and 2013, the trial randomized 500 patients to receive either 70 Gy or 80 Gy, revealing significant improvements in progressio...
|
- Details
- Boris Hadaschik discusses the ongoing PRIMORDIUM phase three trial. The study explores the efficacy of adding six months of apalutamide to ADT in men with high-risk biochemical recurrence post-prostatectomy, evidenced by PSMA-PET imaging. This innovative trial integrates PET imaging not just at baseline but as a primary endpoint, marking a significant leap in utilizing advanced diagnostics to guid...
|
